Summary
42 / 100 · Bulios Score
What speaks for it
- Revenue grew by 163% a year over the last 3 years.
- The price moves less than the market (beta 0.66).
What to watch
- The company made a loss over the last 12 months.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 111% a year over 5 years. Over the last 3 years it grew by 163% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $8.12M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Today's price within the analysts' price targets
The average target of $6 is 257% above today's price.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- UNITED STATES 100%
UNITED STATES brings in 100% of revenue.
Segments in detail